 Sarit Polsky
Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy in Diabetics | 21 | 2025 | 118 | 12.130 |
Why?
| | Diabetes Mellitus, Type 1 | 43 | 2025 | 3601 | 6.510 |
Why?
| | Blood Glucose Self-Monitoring | 26 | 2025 | 596 | 5.970 |
Why?
| | Blood Glucose | 34 | 2025 | 2086 | 5.270 |
Why?
| | Insulin Infusion Systems | 15 | 2025 | 361 | 5.270 |
Why?
| | Hypoglycemic Agents | 17 | 2025 | 1206 | 4.200 |
Why?
| | Insulin | 18 | 2025 | 2311 | 3.250 |
Why?
| | Pregnancy | 28 | 2025 | 6247 | 2.030 |
Why?
| | Hypoglycemia | 8 | 2025 | 427 | 1.690 |
Why?
| | Diabetes, Gestational | 6 | 2024 | 306 | 1.680 |
Why?
| | Pregnancy Outcome | 10 | 2024 | 379 | 1.320 |
Why?
| | Female | 51 | 2025 | 68162 | 0.930 |
Why?
| | Alcohol Drinking | 4 | 2020 | 742 | 0.910 |
Why?
| | Adult | 37 | 2025 | 35361 | 0.820 |
Why?
| | Postnatal Care | 2 | 2021 | 71 | 0.820 |
Why?
| | Pilot Projects | 6 | 2024 | 1545 | 0.730 |
Why?
| | Preconception Care | 1 | 2021 | 39 | 0.710 |
Why?
| | Diabetes Complications | 2 | 2020 | 227 | 0.700 |
Why?
| | Humans | 59 | 2025 | 128896 | 0.700 |
Why?
| | Tobacco Use | 1 | 2018 | 59 | 0.590 |
Why?
| | Spices | 2 | 2014 | 5 | 0.580 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2024 | 2421 | 0.570 |
Why?
| | Young Adult | 17 | 2025 | 12286 | 0.560 |
Why?
| | Pregnant Women | 4 | 2021 | 126 | 0.550 |
Why?
| | Hyperglycemia | 4 | 2022 | 321 | 0.550 |
Why?
| | Fear | 1 | 2019 | 317 | 0.540 |
Why?
| | Postprandial Period | 2 | 2019 | 103 | 0.530 |
Why?
| | Food Preferences | 2 | 2014 | 112 | 0.530 |
Why?
| | Quality of Life | 3 | 2025 | 2706 | 0.520 |
Why?
| | Obesity | 5 | 2019 | 2844 | 0.490 |
Why?
| | Lunch | 1 | 2014 | 7 | 0.470 |
Why?
| | Meat Products | 1 | 2014 | 25 | 0.470 |
Why?
| | Breakfast | 1 | 2014 | 15 | 0.470 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2013 | 0.440 |
Why?
| | Postoperative Care | 1 | 2015 | 246 | 0.420 |
Why?
| | Preoperative Care | 1 | 2015 | 343 | 0.410 |
Why?
| | Insulin Resistance | 3 | 2022 | 1163 | 0.400 |
Why?
| | Infant, Newborn | 5 | 2024 | 5704 | 0.400 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 991 | 0.400 |
Why?
| | Bariatric Surgery | 1 | 2015 | 190 | 0.380 |
Why?
| | Comorbidity | 2 | 2021 | 1542 | 0.380 |
Why?
| | Hypertension | 1 | 2020 | 1236 | 0.380 |
Why?
| | Insulin Aspart | 2 | 2022 | 26 | 0.370 |
Why?
| | Weight Loss | 4 | 2019 | 723 | 0.350 |
Why?
| | Diabetic Neuropathies | 2 | 2022 | 87 | 0.340 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 195 | 0.340 |
Why?
| | Postpartum Period | 2 | 2025 | 332 | 0.340 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 1019 | 0.330 |
Why?
| | Feeding Behavior | 1 | 2014 | 620 | 0.310 |
Why?
| | Prediabetic State | 1 | 2011 | 242 | 0.290 |
Why?
| | Retrospective Studies | 10 | 2024 | 14546 | 0.280 |
Why?
| | Cross-Over Studies | 3 | 2024 | 513 | 0.270 |
Why?
| | Prenatal Care | 2 | 2021 | 272 | 0.260 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 272 | 0.260 |
Why?
| | Feasibility Studies | 2 | 2024 | 859 | 0.250 |
Why?
| | Middle Aged | 20 | 2024 | 30977 | 0.250 |
Why?
| | United States | 9 | 2024 | 13975 | 0.250 |
Why?
| | Gastric Bypass | 2 | 2019 | 106 | 0.250 |
Why?
| | Risk Factors | 9 | 2022 | 9792 | 0.230 |
Why?
| | Cost Savings | 1 | 2024 | 82 | 0.230 |
Why?
| | Labor, Obstetric | 1 | 2024 | 55 | 0.220 |
Why?
| | Registries | 4 | 2020 | 1916 | 0.220 |
Why?
| | Weight Reduction Programs | 2 | 2015 | 107 | 0.220 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 133 | 0.210 |
Why?
| | Single-Blind Method | 1 | 2024 | 273 | 0.210 |
Why?
| | Biomedical Technology | 1 | 2023 | 39 | 0.210 |
Why?
| | Hospitalization | 2 | 2024 | 2080 | 0.210 |
Why?
| | Off-Label Use | 1 | 2023 | 51 | 0.200 |
Why?
| | Patient Admission | 1 | 2024 | 185 | 0.200 |
Why?
| | Insulin Lispro | 1 | 2022 | 36 | 0.200 |
Why?
| | Male | 21 | 2024 | 63146 | 0.190 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.190 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 170 | 0.190 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 35 | 0.190 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 226 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 615 | 0.190 |
Why?
| | Aged | 13 | 2022 | 22035 | 0.180 |
Why?
| | Technology | 1 | 2021 | 83 | 0.180 |
Why?
| | Patient Satisfaction | 1 | 2025 | 639 | 0.180 |
Why?
| | Allopurinol | 1 | 2020 | 58 | 0.170 |
Why?
| | Parity | 1 | 2020 | 120 | 0.170 |
Why?
| | Overweight | 2 | 2015 | 522 | 0.170 |
Why?
| | Xanthine Oxidase | 1 | 2020 | 79 | 0.170 |
Why?
| | Epidemics | 1 | 2021 | 79 | 0.170 |
Why?
| | Glomerular Filtration Rate | 2 | 2020 | 684 | 0.160 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 25 | 0.160 |
Why?
| | Adolescent | 9 | 2024 | 20197 | 0.160 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2668 | 0.160 |
Why?
| | Appetite Regulation | 1 | 2019 | 26 | 0.160 |
Why?
| | Uric Acid | 1 | 2020 | 158 | 0.160 |
Why?
| | Diet, Reducing | 1 | 2019 | 82 | 0.150 |
Why?
| | Sleep | 1 | 2024 | 657 | 0.150 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 233 | 0.150 |
Why?
| | Treatment Outcome | 4 | 2021 | 10239 | 0.140 |
Why?
| | Eczema | 1 | 2018 | 83 | 0.140 |
Why?
| | Telemetry | 1 | 2017 | 39 | 0.140 |
Why?
| | Insulin, Short-Acting | 1 | 2016 | 6 | 0.140 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 827 | 0.130 |
Why?
| | Glucose | 1 | 2021 | 976 | 0.130 |
Why?
| | Infusions, Subcutaneous | 1 | 2016 | 20 | 0.130 |
Why?
| | HIV Infections | 1 | 2011 | 2696 | 0.130 |
Why?
| | Sex Characteristics | 2 | 2018 | 722 | 0.130 |
Why?
| | Self Care | 1 | 2018 | 369 | 0.120 |
Why?
| | Taste | 2 | 2014 | 214 | 0.120 |
Why?
| | Pancreas, Artificial | 1 | 2016 | 70 | 0.120 |
Why?
| | Cheese | 1 | 2014 | 5 | 0.120 |
Why?
| | Body Mass Index | 3 | 2019 | 2244 | 0.120 |
Why?
| | Gastroplasty | 1 | 2014 | 29 | 0.120 |
Why?
| | Pleasure | 1 | 2014 | 20 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 594 | 0.110 |
Why?
| | Life Style | 2 | 2023 | 459 | 0.110 |
Why?
| | Chickens | 1 | 2014 | 187 | 0.110 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 265 | 0.110 |
Why?
| | Delphi Technique | 1 | 2015 | 219 | 0.110 |
Why?
| | Double-Blind Method | 3 | 2024 | 1858 | 0.110 |
Why?
| | Vegetables | 1 | 2014 | 146 | 0.110 |
Why?
| | Skin | 1 | 2018 | 737 | 0.110 |
Why?
| | Menopause | 1 | 2016 | 301 | 0.100 |
Why?
| | Community Health Services | 1 | 2014 | 224 | 0.100 |
Why?
| | Models, Organizational | 1 | 2013 | 147 | 0.100 |
Why?
| | Program Evaluation | 2 | 2014 | 868 | 0.100 |
Why?
| | Glucose Tolerance Test | 2 | 2011 | 356 | 0.100 |
Why?
| | Dietary Fats | 1 | 2014 | 302 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5032 | 0.100 |
Why?
| | Internet | 1 | 2016 | 616 | 0.090 |
Why?
| | Cohort Studies | 3 | 2020 | 5394 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1366 | 0.090 |
Why?
| | Laparoscopy | 1 | 2014 | 452 | 0.090 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2022 | 111 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2021 | 7050 | 0.080 |
Why?
| | Risk Assessment | 1 | 2017 | 3286 | 0.070 |
Why?
| | Telemedicine | 1 | 2016 | 773 | 0.070 |
Why?
| | Diabetic Angiopathies | 2 | 2020 | 263 | 0.070 |
Why?
| | Rural Health Services | 1 | 2007 | 109 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2013 | 896 | 0.070 |
Why?
| | Diet | 1 | 2014 | 1205 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5355 | 0.060 |
Why?
| | Metformin | 1 | 2009 | 307 | 0.060 |
Why?
| | Child | 5 | 2024 | 20824 | 0.060 |
Why?
| | Actigraphy | 1 | 2024 | 88 | 0.050 |
Why?
| | Health Behavior | 1 | 2009 | 732 | 0.050 |
Why?
| | Bionics | 1 | 2022 | 12 | 0.050 |
Why?
| | Bromocriptine | 1 | 2022 | 27 | 0.050 |
Why?
| | Energy Intake | 2 | 2019 | 453 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3787 | 0.050 |
Why?
| | Demography | 1 | 2021 | 280 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2007 | 718 | 0.040 |
Why?
| | Creatinine | 1 | 2022 | 485 | 0.040 |
Why?
| | Aspirin | 1 | 2023 | 379 | 0.040 |
Why?
| | Renin-Angiotensin System | 1 | 2020 | 80 | 0.040 |
Why?
| | Peptide YY | 1 | 2019 | 14 | 0.040 |
Why?
| | Satiation | 1 | 2019 | 23 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2023 | 487 | 0.040 |
Why?
| | Ghrelin | 1 | 2019 | 33 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 345 | 0.040 |
Why?
| | Appetite | 1 | 2019 | 57 | 0.040 |
Why?
| | Sex Factors | 2 | 2018 | 1947 | 0.040 |
Why?
| | Vascular Stiffness | 1 | 2024 | 479 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 614 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4917 | 0.040 |
Why?
| | Albuminuria | 1 | 2019 | 180 | 0.040 |
Why?
| | Income | 1 | 2019 | 191 | 0.040 |
Why?
| | Population Surveillance | 1 | 2021 | 428 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 271 | 0.040 |
Why?
| | Educational Status | 1 | 2019 | 458 | 0.030 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 123 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2016 | 91 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 610 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 734 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 675 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3042 | 0.030 |
Why?
| | Meals | 1 | 2014 | 117 | 0.030 |
Why?
| | Animals | 1 | 2014 | 34628 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1516 | 0.020 |
Why?
| | Focus Groups | 1 | 2014 | 442 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3133 | 0.020 |
Why?
| | Health Education | 1 | 2014 | 324 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2014 | 241 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 581 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1884 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 203 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3874 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2009 | 203 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7060 | 0.020 |
Why?
| | Glucose Intolerance | 1 | 2009 | 142 | 0.020 |
Why?
| | Kenya | 1 | 2007 | 105 | 0.020 |
Why?
| | Accidental Falls | 1 | 2007 | 171 | 0.010 |
Why?
| | Violence | 1 | 2007 | 235 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 6568 | 0.010 |
Why?
| | Colorado | 1 | 2014 | 4443 | 0.010 |
Why?
| | Burns | 1 | 2007 | 286 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2014 | 2494 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2634 | 0.010 |
Why?
|
|
Polsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|